Sign In
Buy CALA
$0.0002
+0 (+0%)
At Close: Jun 03, 2026
Calithera Biosciences Announces 1-for-20 Reverse Stock Split
04:50pm, Tuesday, 14'th Jun 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it ha
Calithera to Present at the H.C. Wainwright Global Investment Conference
07:00am, Tuesday, 17'th May 2022
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Mol
Calithera Biosciences (CALA) Q1 2022 Earnings Call Transcript
06:30am, Wednesday, 11'th May 2022 The Motley Fool
CALA earnings call for the period ending March 31, 2022.
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2022 Results - Earnings Call Transcript
10:04pm, Tuesday, 10'th May 2022
Calithera Biosciences, Inc. (NASDAQ:CALA ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Susan Molineaux - Founder, President & CEO Stephanie Wong - CFO Emil Kuriakose
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
08:05pm, Tuesday, 10'th May 2022 GlobeNewswire Inc.
-- Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 -- SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
01:23pm, Tuesday, 10'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Acquires Biohaven For $11B
Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold
Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
04:05pm, Tuesday, 03'rd May 2022
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Compa
Best Penny Stocks to Buy Under $1 Now? 3 to Watch in May
09:00pm, Thursday, 21'st Apr 2022 PennyStocks
Are these under $1 penny stocks on your watchlist right now?
The post Best Penny Stocks to Buy Under $1 Now? 3 to Watch in May appeared first on Penny Stocks to Buy, Picks, News and Information | Penn
Best Penny Stocks to Buy Under $1 Now? 3 to Watch in May
05:00pm, Thursday, 21'st Apr 2022
Are these under $1 penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Under $1 Now?
Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds
05:01pm, Friday, 08'th Apr 2022 GlobeNewswire Inc.
Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their potential as a therapeutic approach in numerous solid tumor cancers
10 Biggest Price Target Changes For Monday
12:09pm, Monday, 04'th Apr 2022 Benzinga
Keybanc raised the price target on Block, Inc. (NYSE: SQ) from $175 to $180. Block shares rose 2.8% to $137.42 in pre-market trading.
SVB Leerink cut Calithera Biosciences, Inc. (NASDAQ: CALA) pri
Calithera Biosciences (CALA) Q4 2021 Earnings Call Transcript
03:00pm, Friday, 01'st Apr 2022 The Motley Fool
CALA earnings call for the period ending December 31, 2021.
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2021 Results - Earnings Call Transcript
09:49pm, Thursday, 31'st Mar 2022
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2021 Results - Earnings Call Transcript
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
12:14pm, Thursday, 31'st Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Amylyx Says FDA Committee Casts Negative Vote On ALS Drug
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
Calithera Biosciences Raises $10M Via Equity Issued At 10% Discount
11:27am, Wednesday, 30'th Mar 2022
Calithera Biosciences Inc (NASDAQ: CALA) priced its previously announced underwritten public offering of 18.5 million shares at $0.54 per share for gross proceeds of $10 million. Each share of com
